ReviewPharmaceutics2022
Novel Eye Drop Delivery Systems: Advance on Formulation Design Strategies Targeting Anterior and Posterior Segments of the Eye.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Randomized, single-centre, double-blinded repeated dose investigation of safety and tolerability of ocular administrations of a novel silica eye drop product in healthy volunteers.Acta ophthalmologica · 2026Trial
- Punctal and Intracanalicular Drug Delivery Systems for Ophthalmic Use: A Narrative Review of Technologies, Clinical Outcomes, and Critical Quality Attributes.Pharmaceutics · 2026Review
- A gel-forming antioxidant eye drop for photoreceptor protection in retinitis pigmentosa.Drug delivery and translational research · 2026Article
- Ex vivo and computational investigation of corneal iontophoresis to enhance penetration of high-molecular-weight compounds: a study using albumin as a model molecule.Scientific reports · 2026Article
- Nanotherapeutic potential in glaucoma associated ocular cancers.Discover oncology · 2026Review
- Very High Molecular Weight Hyaluronic Acid as an Enhanced Vehicle in Therapeutic Eye Drops: Application in a Novel Latanoprost Formulation for Glaucoma.Bioengineering (Basel, Switzerland) · 2025Review
- The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study.Scientific reports · 2025Article
- Recent advances and prospects of nanoparticle-based drug delivery for diabetic ocular complications.Theranostics · 2025Review
- Mucoadhesive-to-Mucopenetrating Nanoparticles for Mucosal Drug Delivery: A Mini Review.International journal of nanomedicine · 2025Review
- Revolutionizing Retinal Therapy: The Role of Nanoparticle Drug Carriers in Managing Vascular Retinal Disorders.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
- Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases.Journal of nanobiotechnology · 2024Review
- A comprehensive review on alpha-lipoic acid delivery by nanoparticles.BioImpacts : BI · 2024Review
- Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.AAPS PharmSciTech · 2023Review
- Spironolactone Eyedrop Favors Restoration of Corneal Integrity after Wound Healing in the Rat.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Advancements in Nanogels for Enhanced Ocular Drug Delivery: Cutting-Edge Strategies to Overcome Eye Barriers.Gels (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Eye drops are the most common and convenient route of topical administration and the first choice of treatment for many ocular diseases. However, the ocular bioavailability of traditional eye drops (i.e., solutions, suspensions, and ointments) is very low because of ophthalmic physiology and barriers, which greatly limits their therapeutic effect. Over the past few decades, many novel eye drop delivery systems, such as prodrugs, cyclodextrins, in situ gels, and nanoparticles, have been developed to improve ophthalmic bioavailability. These novel eye drop delivery systems have good biocompatibility, adhesion, and propermeation properties and have shown superior performance and efficacy over traditional eye drops. Therefore, the purpose of this review was to systematically present the research progress on novel eye drop delivery systems and provide a reference for the development of dosage form, clinical application, and commercial transformation of eye drops.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.